 | | Vol. 12.19 – 25 May, 2021 |
| |
|
|
| Investigators generated paired single-cell transcriptomic datasets of tumor cells and the bone marrow immune and stromal microenvironment in multiple myeloma.
[Nature Immunology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers investigated the mesenchymal stromal cell’s (MSCs) role in the leukemic niche to define its contribution to the mechanisms of leukemia escape by generating humanized 3D niche with acute myeloid leukemia cells and MSCs derived from either patients or healthy donors.
[Blood] |
|
|
|
| Scientists investigated the combination of FLT3 tyrosine kinase inhibitors (TKIs) with other drugs, and found that the combination of a FLT3 TKI and a BCL-2i synergistically reduced cell proliferation and enhanced apoptosis/cell death in FLT3/ITD cell lines and primary acute myeloid leukemia samples.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Luspatercept pre-treatment of mesenchymal stromal cells increased the subsequent homing of co-cultured hematopoietic stem and progenitor cells in zebrafish embryos.
[Leukemia] |
|
|
|
| Investigators demonstrated that co-targeting LSD1 and one of four identified co-dependent transcription factors exerted synergistic in vitro lethality in acute myeloid leukemia (AML) and post-myeloproliferative neoplasm (MPN) secondary AML cells.
[Blood Cancer Journal] |
|
|
|
| Scientists exposed healthy bone marrow-derived CD34+ hematopoietic stem and progenitor cells (HSPC) to cell-free supernatants derived from acute myeloid leukemia (AML) cell lines to examine proliferation, cell cycling, colony formation, and differentiation of healthy CD34+ HSPC.
[Stem Cells] |
|
|
|
| To explore alternative therapeutics to internal tandem duplication (ITD) of FMS-like tyrosine kinase 3 (FLT3), investigators established a cellular model of monoallelic FLT3ITD/WT cells using the CRISPR-Cas9 system in a human myeloid leukemia cell line.
[Cell Death Discovery] |
|
|
|
| Researchers found that acute lymphoblastic leukemia cells expressing MLL–AF4 fusion protein expressed high levels of lymphoid tissue-specific immunoproteasomes and were sensitive to pharmacologically relevant concentrations of specific immunoproteasome inhibitor ONX-0914.
[Scientific Reports] |
|
|
|
| The authors described the effect of Idelalisib on the PKCβ/NF-κB and Notch pathway in stromal cells upon contact with primary chronic lymphocytic leukemia cells.
[Leukemia & Lymphoma] |
| |
|
|
| Scientists demonstrated the feasibility of generating CD19-specific chimeric antigen receptor (CAR19) T-cells from HLA-matched donors of sibling allogeneic HSC transplant patients via a simple and inexpensive method using the piggyBac transposon.
[Blood] |
|
|
|
| The authors studied the impact of pretreatment with JAK1/2 inhibitor ruxolitinib on patient outcome after allogeneic hematopoietic stem cell transplantation.
[Leukemia] |
|
|
|
| To improve the efficiency of graft-versus-host disease (GvHD) prophylaxis in matched unrelated donor peripheral blood stem cell transplantation, 51 patients with hematological malignancies received a novel regimen for GvHD prophylaxis composed of low dose antithymocyte globulin.
[Bone Marrow Transplantation] |
|
|
|
|
| Studies focusing on multiple myeloma have defined several mutational processes, including a recently identified mutational signature directly caused by exposure to high-dose melphalan.
[Leukemia] |
|
|
|
| Researchers shed light on potential processes driving the plasticity and heterogeneity of granulocyte subsets and discuss the hematopoietic flexibility of granulocyte precursors in bone marrow and the adaptation of myeloid cells to local tissue microenvironments.
[Seminars in Immunopathology] |
|
|
|
| The authors summarize recent advances in knowledge about osteopontin function in the kidney, heart, liver, lung, and hematopoietic stem cell transplantation.
[Archivum Immunologiae Et therapiae Experimentalis] |
|
|
|
|
| Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB reported positive results from the Phase III PRINCE study evaluating the efficacy and safety of EMPAVELI™ in adults with paroxysmal nocturnal hemoglobinuria who are treatment naïve.
[Apellis Pharmaceuticals, Inc. (Globe Newswire, Inc.)] |
|
|
|
| TG Therapeutics, Inc. announced that the FDA has accepted the Biologics License Application for Ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ®, their inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
[TG Therapeutics, Inc. (Globe Newswire, Inc.)] |
|
|
|
|
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | Technische Universität Dresden – Dresden, Germany |
|
|
|
| | Zhejiang University – Zhejiang, China |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
